CNB Bank Has $239,000 Stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

CNB Bank decreased its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 29.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,435 shares of the biopharmaceutical company’s stock after selling 1,015 shares during the quarter. CNB Bank’s holdings in Alexion Pharmaceuticals were worth $239,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Alexion Pharmaceuticals by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 16,649,126 shares of the biopharmaceutical company’s stock valued at $2,180,703,000 after buying an additional 211,960 shares in the last quarter. BlackRock Inc. boosted its stake in Alexion Pharmaceuticals by 1.2% in the 2nd quarter. BlackRock Inc. now owns 16,225,615 shares of the biopharmaceutical company’s stock valued at $2,125,230,000 after buying an additional 199,298 shares in the last quarter. Nuveen Asset Management LLC boosted its stake in Alexion Pharmaceuticals by 57,650.8% in the 2nd quarter. Nuveen Asset Management LLC now owns 3,637,144 shares of the biopharmaceutical company’s stock valued at $476,393,000 after buying an additional 3,630,846 shares in the last quarter. Northern Trust Corp boosted its stake in Alexion Pharmaceuticals by 0.5% in the 2nd quarter. Northern Trust Corp now owns 2,976,327 shares of the biopharmaceutical company’s stock valued at $389,840,000 after buying an additional 15,296 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in Alexion Pharmaceuticals by 0.7% in the 2nd quarter. Bank of America Corp DE now owns 2,078,585 shares of the biopharmaceutical company’s stock valued at $272,253,000 after buying an additional 13,426 shares in the last quarter. 94.68% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages recently commented on ALXN. Citigroup set a $150.00 price target on Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 30th. BMO Capital Markets began coverage on Alexion Pharmaceuticals in a research note on Thursday, September 12th. They issued an “outperform” rating and a $149.00 price objective on the stock. Stifel Nicolaus reissued a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Friday, August 30th. Cowen reissued a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday, October 16th. Finally, William Blair began coverage on Alexion Pharmaceuticals in a research note on Thursday, September 26th. They issued an “outperform” rating and a $146.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $159.00.

Alexion Pharmaceuticals stock opened at $110.79 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.45 and a current ratio of 3.98. The firm has a market cap of $23.73 billion, a P/E ratio of 15.63, a P/E/G ratio of 1.02 and a beta of 1.65. The business’s fifty day moving average is $102.45 and its two-hundred day moving average is $115.69. Alexion Pharmaceuticals, Inc. has a 52 week low of $92.56 and a 52 week high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share for the quarter, topping analysts’ consensus estimates of $2.47 by $0.32. The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.24 billion. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. The firm’s quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.02 earnings per share. On average, equities research analysts predict that Alexion Pharmaceuticals, Inc. will post 9.41 earnings per share for the current year.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: Stock Portfolio Tracker

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.